Adjunctive Therapy In Insulin Treated Type 1 Diabetes Therapeutics
1. Symlin patent expiration
Treatment: Treatment of diabetes with an amylin agonist; Treatment of diabetes with an amylin agonist, including with insulin; Use of an amylin agonist to reduce gastric motility and treat post prandial hypergly...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5814600 | ASTRAZENECA AB | Method and composition for treatment of insulin requiring mammals |
Sep, 2015
(10 years ago) | |
| US5686411 | ASTRAZENECA AB | Amylin agonist peptides and uses therefor |
Mar, 2019
(6 years ago) | |
| US6608029 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2013
(12 years ago) | |
| US6114304 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2017
(8 years ago) | |
Drugs and Companies using PRAMLINTIDE ACETATE ingredient
Market Authorisation Date: 25 September, 2007
Dosage: INJECTABLE
More Information on Dosage
SYMLIN family patents
